Ningbo Health Gene Technologies Co., Ltd, a China-based medical testing solution provider, has reportedly raised “hundreds of millions” of renminbi in a Series C financing round led by SCGC. Other investors included BioTrack Capital, Hefeng Venture Capital, Yingong Venture Capital, and Binjiang Xincheng Development Investment. The proceeds will be directed towards new technology exploration and product development. Previously, the company raised RMB220 million (USD35.5 million) in a Series A financing round in December 2020.
Company Background
Founded in 2011, Health Gene Tech specializes in clinical laboratory molecular diagnostic reagents, nucleic acid detection instruments, and forensic DNA detection reagents. The company has launched a human papilloma (HPV) typing test kit with E6/E7 oncogene as the detection site, which it claims is the first of its kind worldwide. Additionally, it has introduced ResP13, a detection kit for 13 respiratory pathogens, which is touted as the most comprehensive of its kind in China.-Fineline Info & Tech
